# A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center

> **NCT04641676** · NA · UNKNOWN · sponsor: **The Belgian Society of Medical Oncology** · enrollment: 1000 (estimated)

## Conditions studied

- Metastatic Cancer
- Local Tumor Invasion

## Interventions

- **DIAGNOSTIC_TEST:** NGS testing

## Key facts

- **NCT ID:** NCT04641676
- **Lead sponsor:** The Belgian Society of Medical Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-09
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641676, "A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04641676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*